{"denoms":[{"counts":[{"groupId":"BG000","value":"150"},{"groupId":"BG001","value":"155"},{"groupId":"BG002","value":"305"}],"units":"Participants"}],"groups":[{"description":"Participants received Mircera (Methoxy polyethylene glycol-epoetin beta), administered SC at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.","id":"BG000","title":"Mircera"},{"description":"Participants received darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.","id":"BG001","title":"Darbepoetin Alfa"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.37","value":"65.2"},{"groupId":"BG001","spread":"13.40","value":"67.4"},{"groupId":"BG002","spread":"13.91","value":"66.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"172"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"133"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Safety population included all randomized participants who received at least 1 dose of study medication and attended safety follow-up, whether they withdrew prematurely or not. Participants were assigned to the treatment group as treated. One participant randomized to Mircera, received darbepoetin alfa and included in darbepoetin alfa arm."}